BGB Group Revenue and Competitors

Location

N/A

Total Funding

Marketing

Industry

Estimated Revenue & Valuation

  • BGB Group's estimated annual revenue is currently $177.5M per year.(i)
  • BGB Group's estimated revenue per employee is $312,500

Employee Data

  • BGB Group has 568 Employees.(i)
  • BGB Group grew their employee count by 2% last year.

BGB Group's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
Chief People OfficerReveal Email/Phone
4
Chief Client OfficerReveal Email/Phone
5
Chief, Business IntegrationReveal Email/Phone
6
Chief Creative Officer (CCO)Reveal Email/Phone
7
Chief Client OfficerReveal Email/Phone
8
Chief Transformation OfficerReveal Email/Phone
9
Associate VP, Medical Director, Medical Strategy and Scientific ServicesReveal Email/Phone
10
Chief Innovation and IntelligenceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$42.9M1561%N/AN/A
#2
$1266.7M3619-12%N/AN/A
#3
$19.8M798%N/AN/A
#4
$0.4M3-25%N/AN/A
#5
$16.7M74-14%N/AN/A
#6
$15.3M6831%N/AN/A
#7
$1716.8M49055%N/AN/A
#8
$1220.8M3488-19%N/AN/A
#9
$713M199721%N/AN/A
#10
$25.3M1019%N/AN/A
Add Company

What Is BGB Group?

BGB was founded in 2005 by two entrepreneurs: an MD internist and a marketing MBA. With commercial savvy and a passion for science, came a unique fusion of authoritative medical insights with breakthrough creative communications.\n\nToday, BGB is an independent agency of 300+ employees across 5 subsidiaries, BGBNYC, BIONYC, SCIONYC, ICONYC, SYNGENYC, that delivers the best in healthcare communications including medical and marketing consulting, promotional advertising, medical education and digital strategy and execution.

keywords:N/A

N/A

Total Funding

568

Number of Employees

$177.5M

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

BGB Group News

2022-04-20 - Tislelizumab plus chemotherapy significantly extends OS in ...

... seen in the tislelizumab and chemotherapy group in RATIONALE 306. ... Tislelizumab (BGB-A317, BeiGene), a humanized immunoglobulin G4...

2022-04-20 - FDA decisions on new oncological drugs

... single-arm pivotal phase 2 study (BGB-3111–206) conducted in China, ... The use of an optimal control group might increase the external...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$149.1M568N/AN/A
#2
$129.8M5689%$102M
#3
$180.7M569-7%$10.3M
#4
$195.1M5694%$87M
#5
$177.8M5697%N/A